Intro Paragraph
Substudies that have been approved by the Global Trial Steering Committee (GSTC)
Staphylococcus aureus Network: ultrasound for diagnosis of endovascular disease in Paediatrics and Youth
Relation between cefazolin and flucloxacillin exposure and outcome
Difference in the emergence of resistant pathogens between cefazolin and flucloxacillin
Evaluating the impact of a SIMPlified Layered consent process versus a conventional informed consent form on recruitment of potential participants to a large platform clinical trial: a pragmatic nested randomized controlled trial
Optimizing antibiotic dosing in the Staphylococcus aureus Network Adaptive Platform trial
Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.
Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia
Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia
A statistical genomics framework to improve prediction of treatment outcomes of Staphylococcus aureus bacteraemia (SAB)
PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.
Intro Paragraph
Substudies that are in the process of obtaining approval
Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia
Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.
Pilot study for real-time sequencing of Staphylococcus aureus bloodstream isolates
Using a validated penicillin allergy risk prediction tool (Pen-FAST) in patients with a low risk penicillin allergy
Immunopathogenesis and pharmacogenomics of severe antibiotic hypersensitivity
Using microdata to assess the impact of Staphylococcus aureus bacteremia
Ceftriaxone vs (Flu)cloxacillin for S. aureus bacteraemia
Outcomes of Staph aureus Infective endocarditis and cardiac device infections
Dalbavancin vs standard of care for people who inject drugs with Staphylococcus aureus bacteraemia: A pragmatic, multicentre, randomised, non-inferiority trial
Targeting Inequities in Enrolment – an observational study evaluating socio-demographic predictors of participation in the SNAP trial (the SNAP-TIE study)
Are trial treatment effects preserved in patients excluded from the trial? Comparison of cefazolin versus (flu)cloxacillin for MSSA bacteremia in the SNAP registry.
Adjunctive fosfomycin therapy in patients with Staphylococcus aureus bloodstream infection at high risk of complications or relapse
Staphylococcus aureus bacteraemia treated with phage therapy to improve outcomes (SABRE-Phi trial)
C-SNAP: Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial
Professor Joshua S Davis PhD, FRACP, MBBS (Hons), DTM&H, Grad Cert Pop Health. Infectious Diseases Physician and NHMRC Career Development Fellow at the University of Newcastle and the Menzies School of Health Research.
Professor Steven YC Tong PhD, FRACP, MBBS (Hons), Grad Dip Epidemiol Biostats, Infectious Diseases Physician with the Victorian Infectious Diseases Service.
